Topical β-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol

M. G. Lynch, J. T. Whitson, R. H. Brown, H. Nguyen, M. M. Drake

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Topical β-blocking agents have been associated with adverse central nervous system (CNS) effects, including depression, emotional lability, and sexual dysfunction. Two studies were done to determine if patients who developed CNS effects while using timolol maleate would improve with betaxolol hydrochloride. In one study, 18 patients with CNS symptoms during timolol therapy were switched to betaxolol. Sixteen of the 18 patients noted symptomatic improvement with betaxolol. The second study involved seven patients with CNS symptoms during timolol therapy who were entered into a double-masked cross-over study. In two patients CNS symptoms resolved with betaxolol; in three patients symptoms improved; and in one patient symptoms worsened with betaxolol. Although factors influencing β-blocker activity in the CNS are not well understood, there may be some advantage to a selective agent.

Original languageEnglish (US)
Pages (from-to)908-911
Number of pages4
JournalArchives of Ophthalmology
Volume106
Issue number7
StatePublished - 1988

Fingerprint

Betaxolol
Timolol
Central Nervous System
Therapeutics
Cross-Over Studies
Depression

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Topical β-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol. / Lynch, M. G.; Whitson, J. T.; Brown, R. H.; Nguyen, H.; Drake, M. M.

In: Archives of Ophthalmology, Vol. 106, No. 7, 1988, p. 908-911.

Research output: Contribution to journalArticle

@article{b13a795db8554c0386054d9c838591b3,
title = "Topical β-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol",
abstract = "Topical β-blocking agents have been associated with adverse central nervous system (CNS) effects, including depression, emotional lability, and sexual dysfunction. Two studies were done to determine if patients who developed CNS effects while using timolol maleate would improve with betaxolol hydrochloride. In one study, 18 patients with CNS symptoms during timolol therapy were switched to betaxolol. Sixteen of the 18 patients noted symptomatic improvement with betaxolol. The second study involved seven patients with CNS symptoms during timolol therapy who were entered into a double-masked cross-over study. In two patients CNS symptoms resolved with betaxolol; in three patients symptoms improved; and in one patient symptoms worsened with betaxolol. Although factors influencing β-blocker activity in the CNS are not well understood, there may be some advantage to a selective agent.",
author = "Lynch, {M. G.} and Whitson, {J. T.} and Brown, {R. H.} and H. Nguyen and Drake, {M. M.}",
year = "1988",
language = "English (US)",
volume = "106",
pages = "908--911",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Topical β-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol

AU - Lynch, M. G.

AU - Whitson, J. T.

AU - Brown, R. H.

AU - Nguyen, H.

AU - Drake, M. M.

PY - 1988

Y1 - 1988

N2 - Topical β-blocking agents have been associated with adverse central nervous system (CNS) effects, including depression, emotional lability, and sexual dysfunction. Two studies were done to determine if patients who developed CNS effects while using timolol maleate would improve with betaxolol hydrochloride. In one study, 18 patients with CNS symptoms during timolol therapy were switched to betaxolol. Sixteen of the 18 patients noted symptomatic improvement with betaxolol. The second study involved seven patients with CNS symptoms during timolol therapy who were entered into a double-masked cross-over study. In two patients CNS symptoms resolved with betaxolol; in three patients symptoms improved; and in one patient symptoms worsened with betaxolol. Although factors influencing β-blocker activity in the CNS are not well understood, there may be some advantage to a selective agent.

AB - Topical β-blocking agents have been associated with adverse central nervous system (CNS) effects, including depression, emotional lability, and sexual dysfunction. Two studies were done to determine if patients who developed CNS effects while using timolol maleate would improve with betaxolol hydrochloride. In one study, 18 patients with CNS symptoms during timolol therapy were switched to betaxolol. Sixteen of the 18 patients noted symptomatic improvement with betaxolol. The second study involved seven patients with CNS symptoms during timolol therapy who were entered into a double-masked cross-over study. In two patients CNS symptoms resolved with betaxolol; in three patients symptoms improved; and in one patient symptoms worsened with betaxolol. Although factors influencing β-blocker activity in the CNS are not well understood, there may be some advantage to a selective agent.

UR - http://www.scopus.com/inward/record.url?scp=0023801482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023801482&partnerID=8YFLogxK

M3 - Article

C2 - 2898932

AN - SCOPUS:0023801482

VL - 106

SP - 908

EP - 911

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 7

ER -